.jpeg)
Indications for Sacituzumab govitecan in breast cancer
Sacituzumab govitecan is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative cancer and for the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor-positive, human epidermal growth factor receptor2-negative breast cancer who have received other related therapies in the metastatic setting. Gosatuzumab is also indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have been previously treated with platinum-containing chemotherapy and a programmed death receptor-1 (PD-1) or programmed death ligand-1 (PD-L1) inhibitor.
[ 免责声明 ] 本页面内容来自公开渠道（如FDA官网、Drugs官网、原研药厂官网等），仅供持有医疗专业资质的人员用于医学药学研究参考，不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市，不适用于中国境内销售和使用。如需治疗，请咨询正规医疗机构。本站不提供药品销售或代购服务。
